Compare AstraZeneca plc (AZN) vs InMode Ltd (INMD) Price & Performance

AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.

The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.

INMD trades at $15.15, down 0.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company maintains strong profitability with a 77.84% gross margin and a P/E of 11.04, indicating potential undervaluation. Recent news includes an unsolicited acquisition offer at $16.75 per share and upcoming Q2 2026 earnings on August 5, 2026, with revenue guidance of $95.2M-$95.4M.

The outlook is mixed: solid fundamentals and a takeover bid provide upside potential, but risks include earnings misses, legal investigations, and shareholder opposition to the acquisition. Analyst consensus is a $16.50 price target with a balanced buy/hold split, suggesting cautious optimism amid near-term volatility.